Camp4 Therapeutics CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
5AM Ventures entities and associated individuals have amended their Schedule 13D filing, increasing their beneficial ownership in CAMP4 Therapeutics Corporation following a recent closing.
NASDAQ
Enavate Sciences GP and Everest Aggregator have reduced their beneficial ownership in CAMP4 Therapeutics Corporation to 6.0% through recent open market sales.
NASDAQ
Enavate Sciences and Everest Aggregator report a diluted beneficial ownership of 8.1% in CAMP4 Therapeutics Corporation following a private placement, alongside a director's resignation.
NASDAQ
Polaris Partners and affiliated entities increased their beneficial ownership in Camp4 Therapeutics to 8.4% following a $50.1 million private placement.
NASDAQ
5AM Ventures and affiliates increased their beneficial ownership in CAMP4 Therapeutics to 12.5% through a $4.5 million initial private placement.